AMR Sept Banner v2

ASM Attends UN General Assembly

ASM President, Susan Sharp, Ph.D., joined global leaders at the United Nations General Assembly in New York today in a historical meeting to focus on the commitment to fight AMR.
Read

UN General Assembly Focuses on AMR

Leaders at the UN General Assembly draft a plan for coordinated, cross-cutting efforts to improve the current state of AMR.
Read

Superbugs are a 'Fundamental Threat'

If antibiotics were telephones, we would still be calling each other using clunky rotary dials and copper lines," Stefano Bertuzzi, CEO of ASM, told NBC News.
Read
Become a member today!
JOIN ASM
Submit Abstracts for Biothreats 2017
SUBMIT
Antibacterial Development Conference
REGISTER

baseman joel


Dr. Baseman's laboratory studies the biology of pathogenic mycoplasmas and relate these findings to disease pathogenesis in humans and animal models.  Their recent discovery of the Community Acquired Respiratory Distress Syndrome Toxin (CARDS Tx) of Mycoplasma pneumoniae (MPN) represents the first authentic toxin/virulence determinant found in MPN, as the toxin behaves as a bona fide ADP-ribosylating toxin (like the classical ADP-ribosylating toxins of pertussis and diphtheria) and vacuolating toxin (like VacA). CARDS Tx is a remarkable, one-of-a-kind protein; no other toxin or virulence factor exhibits both ADP ribosylation and vacuolating activities and elicits such a distinctive host response, causing unusual pathologies, including unique inflammatory pathways and tissue injury. Based upon the lab's clinical and animal model studies and in vitro observations, they have compelling evidence that CARDS Tx represents a single molecule tightly linked to mediating acute and chronic airway diseases. The lab also examine the sexually transmitted mycoplasma, Mycoplasma genitalium (MGN). They are clarifying MGN virulence determinants that mediate the dynamic interactions between MGN and human target cells, leading to overt clinical disease. Recently, they described the remarkable ability of MGN to exhibit perinuclear and intranucleolar localization, suggesting that this pathogen circumvents host defenses and navigates through host cell structures in order to establish and maintain viability and persistence. Specific gene products of MGN that contribute to this unique trafficking are being identified in order to understand how this mycoplasma elicits pathogenetic consequences and determine what MGN molecules can be used as therapeutic targets to interrupt or prevent disease progression.

 

 

 

TPL_asm2013_SEARCH

91202